The US urothelial carcinoma market is estimated to grow modestly at a CAGR of around 9.6% during the forecast period. The US contributes significantly to the growth of the urothelial carcinoma treatment market in North America. The healthcare spending of the US is significantly high as compared to that of other regions. The US spends almost 17.2% of GDP on healthcare expenditure in 2018. Moreover, the investments in R&D and a surging pool of geriatric population coupled with a high prevalence of urothelial carcinoma is driving the market growth in the US. US Census Bureau estimated that people aged over 65 years represent around 15% of the total population of the country in 2015. This share is further estimated to reach 21% by 2030 and 24% by 2060. Moreover, the US has the presence of some of the key players operating in the urothelial carcinoma market such as Merck & Co, Inc., Pfizer, Inc., and Spectrum Pharmaceuticals, Inc., which further augments the growth of the market in the country.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-urothelial-carcinoma-market
US urothelial carcinoma market is segmented into diagnosis and treatment. Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The cystoscopy procedure is the most commonly used method in the diagnosis and treatment of urothelial carcinoma. The cystoscopy uses special tools that may be passed through cystoscope to treat very small bladder tumors, which might be removed during cystoscopy. Therefore, it is highly adopted for the diagnosis of the disease.
The companies which are contributing to the growth of the US urothelial carcinoma market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc., and Spectrum Pharmaceuticals, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
US Urothelial Carcinoma Market- Segmentation
By Diagnosis
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (IVP)
- Others (Biomarkers)
By Treatment
- Surgery
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Others (Targeted Therapy)
A full report of US Urothelial Carcinoma Market is available at: https://www.omrglobal.com/industry-reports/us-urothelial-carcinoma-market
